Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer

被引:44
|
作者
Burrell, Rebecca A. [1 ]
Juul, Nicolai [2 ]
Johnston, Stephen R. [3 ]
Reis-Filho, Jorge S. [4 ]
Szallasi, Zoltan [2 ,5 ]
Swanton, Charles [1 ,3 ]
机构
[1] London Res Inst, Translat Canc Therapeut Lab, London WC2A 3PX, England
[2] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark
[3] Royal Marsden Hosp, Breast Unit, Dept Med, Sutton SM2 5PT, Surrey, England
[4] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[5] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA 02115 USA
关键词
CHROMOSOMAL INSTABILITY; HER2; BREAST CANCER; DRUG RESISTANCE; TUMOUR HETEROGENEITY; MICROTUBULE; CEP17; SPINDLE ASSEMBLY CHECKPOINT; TAXOL-INDUCED APOPTOSIS; IN-SITU HYBRIDIZATION; PHASE-II TRIAL; MITOTIC CHECKPOINT; 1ST-LINE TREATMENT; INTRATUMORAL HETEROGENEITY; RETROSPECTIVE ANALYSIS; KARYOTYPIC COMPLEXITY; ADJUVANT CHEMOTHERAPY;
D O I
10.1002/jcb.22781
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosomal instability (CIN) is a common cause of tumour heterogeneity and poor prognosis in solid tumours and describes cell-cell variation in chromosome structure or number across a tumour population. In this article we consider evidence suggesting that CIN may be targeted and may influence response to distinct chemotherapy regimens, using HER2-positive breast cancer as an example. Pre-clinical models have indicated a role for HER2 signalling in initiating CIN and defective cell-cycle control, and evidence suggests that HER2-targeting may attenuate this process. Anthracyclines and platinum agents may target tumours with distinct patterns of karyotypic complexity, whereas taxanes may have preferential activity in tumours with relative chromosomal stability. A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer. J. Cell. Biochem. 111: 782-790, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:782 / 790
页数:9
相关论文
共 50 条
  • [21] Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer
    Phelps-Polirer, Kendall
    Abt, Melissa A.
    Smith, Danzell
    Yeh, Elizabeth S.
    PLOS ONE, 2016, 11 (04):
  • [22] Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future
    Ishwaria M. Subbiah
    Ana Maria Gonzalez-Angulo
    Current Treatment Options in Oncology, 2014, 15 : 41 - 54
  • [23] Inhibition of invasion of HER2-positive breast cancer cells by lysosome targeting drugs
    Hansen, Malene B.
    Postol, Maria
    Egan, Davig A.
    Jaattela, Marja
    Kallunki, Tuula
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future
    Subbiah, Ishwaria M.
    Gonzalez-Angulo, Ana Maria
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (01) : 41 - 54
  • [25] Targeting Alternative Pathways in HER2-Positive Breast Cancer RASTOGI Article Reviewed
    Rastogi, Priya
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 415 - 416
  • [26] Treatment of HER2-Positive Metastatic Breast Cancer
    van Ramshorst, Mette S.
    Sonke, Gabe S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1964
  • [27] Immunotherapies against HER2-Positive Breast Cancer
    Duro-Sanchez, Santiago
    Alonso, Macarena Roman
    Arribas, Joaquin
    CANCERS, 2023, 15 (04)
  • [28] Progression and treatment of HER2-positive breast cancer
    April Davoli
    Barbara A. Hocevar
    Thomas L. Brown
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 611 - 623
  • [29] Hereditary component of HER2-positive breast cancer
    Iglesias Campos, M.
    Jimena Marquez, A.
    Peralta Linero, R. J.
    Alba Conejo, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1325 - S1325
  • [30] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283